All
With Less Intense, More Effective Treatments, Survivors of Childhood Cancers are Living Longer
June 5th 2015Better treatment and follow-up are being credited with a reduction in the likelihood that survivors of childhood cancers will later die of illnesses caused by their therapy, such as new malignancies or cardiac or lung disease.
For Small Brain Metastases, Side Effects of Whole Brain Radiation Outweigh Benefits
June 5th 2015When cancers that originate elsewhere cause small metastases in the brain, initial treatment should not routinely be followed by whole brain radiation therapy, because that strategy dramatically increases the chances of cognitive decline without improving survival outcomes.
Patients to be Treated Based on Tumor Genomics, Not Disease Type, in ASCO's First Clinical Trial
June 5th 2015The American Society of Clinical Oncology is testing what will happen if patients are treated according to the genomics of their tumors, rather than on the basis of their disease types, such as breast or colorectal cancers.
With Micrometastases in Melanoma, Complete Node Removal May be Unnecessary
June 2nd 2015When melanoma metastacizes, the lymph node to which it has spread is typically removed. But what if micrometastases are found in other nearby lymph nodes? Should patients undergo a complete dissection, or removal, of all the nodes in the area?
Removing Neck Nodes Before the Spread of Oral Cancer Saves More Lives
June 2nd 2015Removing lymph nodes in the neck before they are affected by oral squamous cell cancer is a life-saving measure and should be adopted as a new standard in treating the disease, according to the results of a phase 3 study.
Time to Progression in CLL Improves 80 Percent with Imbruvica Plus Standard Drugs
June 2nd 2015Adding the targeted drug Imbruvica to a standard combination treatment reduced the risk of disease progression by 80 percent compared with the standard combination alone in patients with pretreated CLL or SLL.
Adding Ibrance to Faslodex Delays Progression of Hormone Receptor-Positive Breast Cancer
June 1st 2015By adding the targeted drug Ibrance to the hormonal drug Faslodex, women with previously treated hormone receptor (HR)-positive, HER2-negative breast cancer delayed disease progression by more than five months.
In Relapsed NHL, Time to Progression Doubles when Gazyva is Added to Rituxan
June 1st 2015Patients with relapsed indolent non-Hodgkin lymphoma who took the anti-CD20 agent Gazyva with Treanda, rather than Treanda alone, doubled their time until further disease progression during the phase 3 GADOLIN study.
Keytruda Works Well in Cancers Marked by Faulty DNA Repair Mechanism
June 1st 2015Patients with heavily pretreated colorectal cancer who harbored genetic defects in DNA mismatch repair (MMR) experienced high response rates when treated with the PD-1 inhibitor Keytruda (pembrolizumab) in a recent study.
Opdivo Sparks Greater Survival Benefit than Docetaxel in Lung Cancers
June 1st 2015The immunotherapy Opdivo (nivolumab) has been shown to convey an overall survival (OS) benefit superior to that offered by the chemotherapy docetaxel in both nonsquamous and squamous non–small cell lung cancer (NSCLC).
Keytruda Doubles Efficacy of Only Targeted Therapy for Head and Neck Cancer
May 31st 2015The immunotherapy Keytruda (pembrolizumab), in a recent study, proved twice as effective for the treatment of head and neck cancer as Erbitux (cetuximab), the only targeted therapy indicated as a therapy for the disease.
EndBrainCancer Now Initiative Works to Support, Educate and Expand Survivorship for Patients
May 28th 2015Aug. 27, 2000, started as an ordinary day for Dellann Elliott Mydland. She and her husband Chris Elliott and their two children, then 5 and 8 years old, had just finished up a weekend at their cabin and were preparing to relax by the grill at home.